CTKB Cytek Biosciences
- 6.300
- +0.120+1.94%
- 6.300
- 0.0000.00%
Cytek Biosciences News
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytek Biosciences (CTKB), Elanco Animal Health (ELAN) and Atara Biotherapeutics (ATRA)
Cytek Biosciences Is Maintained at Overweight by Piper Sandler
Cytek Biosciences Is Maintained at Overweight by Piper Sandler
Cytek Biosciences Price Target Cut to $8.50/Share From $10.00 by Piper Sandler
Cytek Biosciences Price Target Cut to $8.50/Share From $10.00 by Piper Sandler
Piper Sandler: Maintaining the Cytek Biosciences (CTKB.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $10.00 to $8.50.
Piper Sandler: Maintaining the Cytek Biosciences (CTKB.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $10.00 to $8.50.
Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $8.5
Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $10 to $8.5.
Cytek Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 34.92% Piper Sandler $10 → $8.5 Maintains Overweight 03/06/2024 58.73% Piper Sandler $11 → $10
Earnings Call Summary | Cytek Biosciences(CTKB.US) Q1 2024 Earnings Conference
The following is a summary of the Cytek Biosciences, Inc. (CTKB) Q1 2024 Earnings Call Transcript:Financial Performance:Cytek reported a Q1 revenue of $44.9 million, up 21% year-over-year.Gross profit
Cytek Biosciences Inc (CTKB) Q1 2024 Earnings: Revenue Surges, Yet Net Loss Persists
Cytek Biosciences (CTKB) Receives a Buy From Piper Sandler
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Tops Revenue Estimates
Cytek Biosciences GAAP EPS of -$0.05, Revenue of $44.9M
Earnings Flash (CTKB) CYTEK BIOSCIENCES Reports Q1 Revenue $44.9M, Vs. Street Est of $43.6M
04:49 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (CTKB) CYTEK BIOSCIENCES Reports Q1 Revenue $44.9M, vs. Street Est of $43.6M
Cytek Biosciences | 10-Q: Quarterly report
Cytek Biosciences Q1 2024 Adj EPS $(0.05) Misses $(0.04) Estimate, Sales $44.900M Beat $43.586M Estimate
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. The company reported quarterly sales of $44.900 mi
Cytek Biosciences, Inc. (CTKB) Stock Moves -0.33%: What You Should Know
Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
FREMONT, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the first
Cytek Biosciences(CTKB.US) Officer Sells US$117.4K in Common Stock
$Cytek Biosciences(CTKB.US)$ Officer Yan Ming sold 20,000 shares of common stock on Apr 19, 2024 at an average price of $5.87 for a total value of $117.4K.Source: Announcement What is statement of cha
Cytek Biosciences(CTKB.US) Officer Sells US$13,304 in Common Stock
$Cytek Biosciences(CTKB.US)$ Officer Yan Ming sold 1,900 shares of common stock on Apr 9, 2024 at an average price of $7 for a total value of $13,304.Source: Announcement What is statement of changes
Form 144 | Cytek Biosciences(CTKB.US) Officer Proposes to Sell 268K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 9, $Cytek Biosciences(CTKB.US)$ Officer MING YAN intends to sell 40,000 shares of its common stock on Apr 9, with a total market value of approximately $268K. MING YAN ha
Optimistic Outlook: Cytek Biosciences Poised for Growth With New CFO Appointment
Analysis
Price Target
No Data
